STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMUX
  4. [Form 4/A] Immunic, Inc. Amended Insider Trading Activity

Immunic Executive Shows Faith in Company with Share Purchase and Major Option Grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

This Form 4/A amends a previously filed Form 4 for Jason Tardio, President and COO of Immunic (IMUX), correcting an administrative error in reported stock option grants from June 5, 2025.

Key transactions reported:

  • Purchase of 12,512 shares of common stock at $0.79 per share
  • Grant of 598,500 stock options at an exercise price of $0.7729, expiring June 5, 2035

The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. This amendment corrects the number of stock options originally reported in the June 9, 2025 filing.

Positive

  • President and COO Jason Tardio demonstrated confidence through a direct open market purchase of 12,512 shares at $0.79 per share ($9,884 total)
  • Tardio received a significant stock option grant of 598,500 shares with 4-year vesting, aligning long-term interests with shareholders

Negative

  • None.
Insider Tardio Jason
Role President and COO
Bought 12,512 shs ($10K)
Type Security Shares Price Value
Grant/Award Stock Option 598,500 $0.00 --
Purchase Common Stock 12,512 $0.79 $10K
Holdings After Transaction: Stock Option — 598,500 shares (Direct); Common Stock — 12,512 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tardio Jason
(Last) (First) (Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200
(Street)
NEW YORK NY 10036
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/09/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/05/2025 P 12,512 A $0.79 12,512 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $0.7729 06/05/2025 A 598,500 (1) 06/05/2035 Common Stock 598,500 $0.00 598,500 D
Explanation of Responses:
1. 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.
Remarks:
This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 9, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.
/s/ Jason Tardio 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many IMUX shares did President and COO Jason Tardio purchase on June 5, 2025?

Jason Tardio purchased 12,512 shares of IMUX common stock at a price of $0.79 per share on June 5, 2025.

What stock options were granted to IMUX's President and COO in June 2025?

On June 5, 2025, Jason Tardio was granted 598,500 stock options with an exercise price of $0.7729 per share. The options expire on June 5, 2035.

What is the vesting schedule for IMUX COO Jason Tardio's stock options granted in June 2025?

The stock options vest as follows: 25% vest on the first anniversary of the grant date (June 5, 2026), with the remaining 75% vesting in equal monthly increments over the following 36 months.

Why did IMUX file a Form 4/A amendment for Jason Tardio's trades?

The Form 4/A was filed to correct an administrative error in the original Form 4 filed on June 9, 2025, which incorrectly reported the number of stock options granted to Jason Tardio.